Pred Forte 1%

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pred Forte 1%

What is Pred Forte 1%? (Overview)

Property Description
Active ingredient Prednisolone Acetate (1% w/v)
Form Ophthalmic Suspension (Microfine)
Pharmacological class Corticosteroid (Glucocorticoid)
General purpose Management of Ocular Inflammation
Origin Synthetic Adrenocorticoid

What Type of Ophthalmic Medication is Pred Forte 1%?

Pred Forte 1% is a prescription-only ophthalmic suspension containing the synthetic corticosteroid known as Prednisolone Acetate as its single active ingredient. This medication is definitively classified as a glucocorticoid, a pharmacological class that is widely recognized for its potent anti-inflammatory action. The formulation is intended for the localized suppression of inflammation in the eye, addressing symptoms that are established as responsive to steroid therapy.

How is the Prednisolone Acetate Suspension Formulated?

The medication is administered for topical ophthalmic use, delivered as a microfine suspension at a strength of 1% w/v. This is a key differentiating factor; the formulation utilizes the less soluble acetate salt of Prednisolone, which remains suspended in the aqueous vehicle rather than being fully dissolved. This physical characteristic of the suspension is designed to maximize the contact time of the active compound on the ocular surface, enabling effective, sustained delivery to the inflammatory sites within the eye tissues.

What is the General Therapeutic Purpose of Pred Forte 1%?

The primary purpose of this preparation is to provide comprehensive control over localized ocular inflammation. The active compound performs immune system modulation by inhibiting the various biological steps that lead to inflammation, including vascular dilation and the migration of inflammatory cells. This action is generally intended to relieve the discomforting physical manifestations of inflammation, such as redness, swelling (edema), burning, and irritation—a common need following specific surgical procedures or due to non-infectious conditions in adults.

Regulatory References

  1. NIH DailyMed

What side effects are possible with Pred Forte 1%?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse effects and safety characteristics of Pred Forte 1% as described in governmental regulatory documents, such as the FDA Prescribing Information and the UK Summary of Product Characteristics (SmPC).


Ocular Adverse Reactions and Frequency

The primary adverse effects are localized to the eye. According to regulatory data, effects documented in decreasing order of frequency (or common) include Elevation of Intraocular Pressure (IOP), Posterior Subcapsular Cataract formation, and Delayed Wound Healing. Infrequent reactions include damage to the Optic Nerve.

Reactions where the frequency is not known (based on post-marketing reports) include transient burning and stinging upon instillation, headache, eye pain, foreign body sensation, ocular irritation, and a change in the sense of taste (dysgeusia).

System-Organ Class (SOC) Examples of Officially Listed Reactions
Eye Disorders Glaucoma, Cataracts, Conjunctival Hyperemia, Keratitis, Ptosis (droopy eyelids), Mydriasis, Blurred Vision
Nervous System Headache
Gastrointestinal Dysgeusia (change in taste)

Serious Adverse Reactions and Duration-Related Risks

Official labeling documents the following clinically significant risks:

  • Glaucoma: A serious risk associated with prolonged use, potentially leading to optic nerve damage.
  • Secondary Ocular Infection: Prolonged use can suppress the local immune response, increasing the hazard of viral, fungal, or bacterial infection or masking the signs of an active infection.
  • Perforation of the Globe: This risk is heightened when the medication is used in conditions that cause thinning of the cornea or sclera.
  • Systemic Hypercorticoidism: Extremely rare systemic effects, such as Cushing's syndrome or adrenal suppression, are documented, particularly with very frequent use.

Population and Formulation Safety Notes

Regulatory documents include specific safety statements concerning certain populations and formulation components:

  • Pregnancy: Use is generally reserved for situations where the potential benefit is deemed to justify the potential risk to the fetus.
  • Nursing Mothers: Not recommended, as the active ingredient may appear in breast milk and interfere with the infant's growth or hormone production.
  • Pediatrics: Increased monitoring of IOP is required, and there is a specific warning regarding the risk of systemic effects (e.g., adrenal suppression) in very young children.
  • Formulation Constraints: The product contains sodium bisulfite, which may cause allergic reactions in susceptible individuals, and benzalkonium chloride, which can be absorbed by soft contact lenses.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Prednisolone Acetate Ophthalmic Suspension 1% primarily defines overdose risk based on exposure duration and not acute application volume. Acute overdosage resulting from accidental over-application to the eye is officially documented as not ordinarily expected to cause acute systemic problems.

The primary concern highlighted in regulatory documentation arises from chronic, excessive topical use, which may lead to sufficient systemic absorption of the corticosteroid. This sustained exposure carries the documented risk of developing hypercorticism, presenting as clinical features associated with Cushing's syndrome, and suppression of the Hypothalamic-Pituitary-Adrenal (HPA) axis. HPA axis suppression is classified as a serious outcome of chronic overdose that may require specific medical management upon discontinuation.

In the event the ophthalmic suspension is accidentally ingested, the regulatory advice is to drink fluids to dilute the product. Despite the low risk for acute topical effects, immediate medical attention must be sought for any persistent or severe adverse symptoms related to excessive use or accidental ingestion. Management for overdose is defined as strictly symptomatic and supportive treatment, as the official labeling states that no specific antidote is known. Furthermore, the official prescribing information notes that pediatric patients may be more susceptible to HPA axis suppression due to their body surface area-to-weight ratio, which necessitates careful monitoring if systemic exposure is suspected after prolonged use.

Therapeutic Uses of Pred Forte 1%

What Pred Forte 1% Treats: Main Uses and Benefits

The therapeutic focus of Pred Forte 1% (prednisolone acetate ophthalmic suspension) is centered on the management of steroid-responsive inflammation affecting the anterior segment of the eye. The scope is relevant for conditions involving the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.


Key Therapeutic Applications and Benefits

This medication is commonly used to help with acute and severe inflammation in conditions such as iritis, cyclitis, and certain forms of keratitis. It is also applied across domains where additional symptomatic support is needed to mitigate the pronounced reaction that arises following eye surgery, such as cataract removal, and in cases of inflammation from eye injuries or chemical burns. The treatment's primary benefit is that it supports the patient during difficult episodes by easing distress from intense manifestations like swelling, pronounced redness, persistent irritation, and inflammation-related soreness. This assists with maintaining a sense of stability when symptoms interfere with routine activities.


Quick Fact: Symptomatic Support for Acute Eye Inflammation

This medication may assist with symptomatic relief by addressing the physical discomfort associated with active inflammation, contributing to easing the overall symptom load during acute episodes.

Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Pred Forte 1%?

The population eligibility for Pred Forte 1% (prednisolone acetate ophthalmic suspension) is strictly governed by regulatory documentation, primarily defined by the patient's existing ocular health status and age.

Contraindicated Populations (Must Not Use)

Use of this medicine is absolutely contraindicated in patients with specific active ocular infections, including Epithelial Herpes Simplex Keratitis (dendritic keratitis) and most other viral diseases of the cornea and conjunctiva, such as Vaccinia and Varicella. It is also prohibited in cases of active mycobacterial infection of the eye, fungal diseases of ocular structures, or acute untreated purulent ocular infections. Individuals with a known hypersensitivity to any component of the formulation must not use it.

Age and Physiological Restrictions

Safety and effectiveness are not established in the pediatric population younger than 2 years of age. For older adults, no overall differences in safety or effectiveness have been identified. The medication's use is restricted in patients with pre-existing corneal or scleral thinning, as regulatory labeling indicates a risk of perforation.

Use during pregnancy or lactation is considered conditional; official labeling advises use only if the potential benefit justifies the potential risk to the fetus, and generally recommends caution or discontinuation of nursing.

What should I know about interactions with other medicines?

The officially documented interaction profile for Pred Forte 1% (prednisolone acetate ophthalmic suspension) reflects two primary categories of risk, as stated in regulatory labeling.

Pharmacodynamic Interaction with Topical Eye Medicines

Co-administration with Topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is officially noted in prescribing information. This is a pharmacodynamic interaction where the combined use may increase the risk of developing corneal adverse events, including delayed healing, corneal epithelial breakdown, or perforation. This risk is a significant regulatory caution, particularly relevant to patients with pre-existing corneal damage.

Systemic Pharmacokinetic Interactions

The second category involves systemic pharmacokinetic interactions, primarily with strong CYP3A4 inhibitors. Regulatory documents note that co-administration with potent inhibitors of this enzyme, such as ritonavir or cobicistat, is expected to increase the systemic exposure of prednisolone by decreasing its clearance. Although the clinical relevance of this increase is generally low due to the minimal systemic absorption of the ophthalmic formulation, this interaction pattern is formally documented by regulatory authorities. No restrictions or cautions related to food, alcohol, or herbal products are documented in the official prescribing information.

Mechanism of Action

Prednisolone acetate, the active compound, is a synthetic glucocorticoid that rapidly penetrates the cell membranes of targeted anterior ocular tissues.

Molecular Pathway

The molecule acts as an agonist for the cytoplasmic glucocorticoid receptor (GR). Upon ligand binding, the steroid-receptor complex undergoes conformational change and translocates into the cell nucleus. Inside the nucleus, the complex binds to specific glucocorticoid response elements (GREs) on the DNA, modulating gene transcription. This genomic action results in the inhibition of gene transcription for numerous pro-inflammatory proteins, including certain cytokines, chemokines, and adhesion molecules.

Intracellular Consequences

Concurrently, the mechanism involves the induction of gene transcription for anti-inflammatory proteins, such as lipocortin-1 (annexin A1). Lipocortin-1 acts as a negative regulator of the enzyme phospholipase A2, thereby preventing the cleavage of membrane phospholipids and the subsequent release of arachidonic acid. This cascade ultimately suppresses the biosynthesis of potent inflammatory mediators, including prostaglandins and leukotrienes.

System-Level Modulation

At the physiological level, this dual transcriptional modulation results in a broad inhibition of the acute inflammatory response components. Specifically, it reduces capillary dilation, minimizes fibrin deposition, decreases phagocytic leukocyte migration to the site of irritation, and suppresses excessive capillary proliferation and collagen deposition.

Dosage and Administration Information

Administration Instructions for Pred Forte 1%

Pred Forte (prednisolone acetate 1%) is an ophthalmic suspension for topical use in the eye. The following guidelines describe the administration steps and dosing rules.

Preparation and Route

  • Shake well before using to ensure the medication is properly mixed.
  • The route of administration is ocular instillation (into the conjunctival sac).
  • To prevent contamination, do not touch the bottle tip to the eye, eyelid, or any other surface.

Dosing Schedule (Adults)

Stage Dosing Frequency Amount
Standard Two to four times daily One to two drops per affected eye
Initial Phase (24–48 hours) Up to every hour Two drops per affected eye

Care should be taken not to discontinue therapy prematurely. If signs and symptoms fail to improve after two days, the patient must be re-evaluated by a healthcare professional.

Special Procedural Steps

  1. If you wear soft contact lenses, remove them before application. Wait at least 15 minutes before reinserting them.
  2. Immediately following the instillation of each drop, it is recommended to compress the lacrimal sac at the inner corner of the eye (punctal occlusion) for 1 minute to reduce potential systemic absorption.

Missed Dose

If a dose is missed, instill the drops as soon as you remember. If it is almost time for the next scheduled dose, skip the missed dose and continue with the regular schedule. Do not use a double dose to make up for the forgotten one.

Use in Children

Safety and effectiveness in the pediatric population have not yet been established; therefore, no routine posology can be recommended without a physician's determination.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pred Forte 1%

Evidence for Use in Post-Operative Ocular Inflammation

Research has examined Pred Forte 1% in short-term, randomized clinical trials following routine eye surgeries, such as cataract surgery. These studies were generally designed to evaluate the medication in study groups alongside a placebo (an inactive eye drop) or alongside other active treatments. Researchers monitored several outcomes related to inflammatory or irritative states, mainly focusing on visual signs of inflammation inside the eye, which are measured using scores for anterior chamber cell and flare.

Studies reported patterns related to these inflammation scores observed over the first few weeks following surgery. Findings describe patterns observed in the studies where findings show a greater number of participants in one study group achieved an inflammation score of zero compared to the placebo group during the limited study timeframe. Research describes changes measured during the study period in scores for redness, swelling, and physical discomfort. Intraocular pressure (IOP) was also observed in all study groups as a part of the safety monitoring within the research.

Evidence for Use in Steroid-Responsive Anterior Segment Inflammation

Pred Forte 1% was studied for use in treating inflammation in the front of the eye, such as anterior uveitis, a condition characterized by fluctuating or episodic manifestations. The research was evaluated in active-controlled trials. These trials examined how quickly patients achieved complete resolution of visible inflammation, focusing on outcomes linked to inflammatory or irritative states, specifically the clearing of anterior chamber cells. Research describes the timeframes observed for trial participants to achieve the defined outcome of zero anterior chamber cells.

Long-Term Studies and Follow-Up Data

Currently, long-term effects are not fully established regarding the use of Pred Forte 1%. The research studies monitored outcomes for a defined duration, usually lasting only a few weeks to a couple of months, which is common for acute treatment research. Follow-up durations were limited, and there is limited information for long-term outcomes related to the durability of the treatment's impact or the stability of the eye over extended periods.

What is Still Uncertain About Pred Forte 1% Research

Even with existing clinical data, certainty remains low in several key areas. Limited information for long-term outcomes is a major gap. Comparative evidence is lacking for some newer ophthalmic anti-inflammatories, as most trials compare Pred Forte to older, established treatments. Furthermore, evidence quality varies across studies, and sample sizes were modest in some of the smaller comparative research. This means the research does not provide definitive, universal answers, and the findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Pred Forte 1% (FAQ)


Q: What is the difference between Pred Forte and Pred Mild?

A: Pred Forte 1% is an ophthalmic suspension containing prednisolone acetate at a 1% concentration. While official labeling defines Pred Forte, it does not directly define Pred Mild. However, Pred Mild is known in clinical practice as an eye drop containing a lower concentration (0.12%) of the same active ingredient. These differences in concentration are consistent with their approved use for varying therapeutic needs, as described in official documents.


Q: How quickly does Pred Forte start working after starting treatment?

A: Regulatory studies for this medication typically examine how quickly visible signs of inflammation, such as swelling and redness, resolve over a period of days to weeks. The official documents do not state an exact time for the onset of action (the very first moment the drug begins working). Study outcomes often describe measured improvements in inflammatory signs during the first few days of use.


Q: Does Pred Forte relieve eye itching?

A: Pred Forte is indicated for treating steroid-responsive inflammation in the eye. Inflammation can manifest with symptoms like redness, swelling, burning, and irritation. While the drug's primary action is anti-inflammatory, official documents do not explicitly list itching relief as a stated indication.


Q: Is it normal to feel a sting when using Pred Forte 1%?

A: Official product information notes that transient burning and stinging upon instillation is a documented adverse reaction reported with the use of the suspension. This sensation is typically temporary and localized to the eye. Other temporary feelings like ocular irritation are also documented in post-marketing reports, meaning they are experienced by some users but may not have a known frequency.


Q: Can Pred Forte 1% cause light sensitivity (photophobia)?

A: While the official labeling lists related adverse events like blurred vision and eye pain, photophobia (light sensitivity) is not one of the specific adverse events explicitly documented. If new or worsening sensitivity to light occurs, a healthcare professional should be consulted.


Q: Can Pred Forte affect my vision while I am using it?

A: Yes, official labeling indicates that the use of this medication may cause short-lasting blurring of vision immediately after instillation. Furthermore, blurred vision is listed as a potential side effect. Users should be aware of this possibility when using the eye drops.


Q: Is Pred Forte 1% ever used for treating dry eyes?

A: The primary indication for this drug is the treatment of steroid-responsive inflammation in the anterior segment of the eye. It is not specifically listed in official documents as a primary or sole treatment for chronic dry eye syndrome. Use is generally reserved for conditions where inflammation is the core issue.


Q: Is there a rebound effect when stopping Pred Forte?

A: Official administration instructions advise that therapy should not be discontinued prematurely. While the term 'rebound effect' is not used in the label, discontinuing corticosteroid treatment too soon may lead to the return or worsening of the original inflammation. The prescribed regimen is determined by a healthcare professional.


Q: Can Pred Forte 1% cause long-term eye problems?

A: Official regulatory warnings advise that prolonged use of this medication is associated with serious risks. These risks include the development of a posterior subcapsular cataract and the elevation of intraocular pressure (IOP), which can potentially lead to glaucoma (optic nerve damage). The official label notes that use of the drug for ten days or longer is one reason that monitoring of intraocular pressure is advised.


Q: Are there any non-eye related side effects reported for Pred Forte?

A: Yes, although the medication is applied locally to the eye, some non-ocular adverse reactions are documented. These include headache and a change in the sense of taste (dysgeusia). Additionally, in very rare cases with prolonged, frequent use, there is a risk of systemic effects like adrenal suppression.


Q: Can Pred Forte be used in both eyes if only one eye has symptoms?

A: Regulatory dosage instructions specify the use of the drops in the affected eye(s). This means that the medication can be administered to both eyes if the condition requires bilateral treatment. A healthcare professional determines the appropriate use based on the specific condition.


Q: What happens if I use Pred Forte for longer than prescribed?

A: Using this product for a longer duration than prescribed carries an increased risk of serious adverse effects noted in the official labeling. Specifically, use for 10 days or longer is associated with the documented risks of elevated intraocular pressure and secondary ocular infections.


Q: Are there any drug-drug interactions that are considered serious with Pred Forte?

A: Yes, regulatory information documents two categories of serious interactions. Co-administration with certain Topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may increase the risk of corneal adverse events. Additionally, potent systemic inhibitors of the CYP3A4 enzyme (such as ritonavir or cobicistat) are expected to increase the systemic exposure of prednisolone, which is noted as a significant interaction.


Q: How is the research evidence for Pred Forte described by regulatory bodies?

A: The research evidence for the drug, as reviewed by regulatory bodies, primarily consists of short-term clinical trial findings. These studies are designed to evaluate outcomes related to inflammatory states, such as the reduction of redness and swelling following surgery. Official documents summarize these findings to establish the drug's use for steroid-responsive inflammation.


Q: Can I use Pred Forte if I have had cataract surgery previously?

A: Official research and indications show that Pred Forte is frequently studied and indicated for the treatment of post-operative inflammation following eye surgeries, including cataract surgery. A prior history of cataract surgery is not listed as a contraindication for its use, but the application and duration would be determined by a specialist.


Q: What if I accidentally swallow a small amount of the eye drop?

A: Official documents state that if the eye drop is accidentally ingested, acute problems are not ordinarily expected due to the minimal quantity involved. The official guidance for accidental ingestion advises that drinking fluids to dilute the product in the stomach is recommended, as acute problems are not typically expected.


Q: Is Pred Forte used for allergic conjunctivitis?

A: The official indication for this drug is to treat steroid-responsive inflammation of the conjunctiva (the clear membrane covering the white of the eye). While allergic conjunctivitis is a common cause of such inflammation, the official label uses the broader, non-specific term for inflammation that responds to steroid treatment.


Q: Can Pred Forte be used by people with diabetes?

A: While the topical eye drop has minimal systemic absorption, a history of systemic diseases like diabetes is often noted as a potential risk factor for developing increased intraocular pressure when using corticosteroids. Individuals with diabetes are among those for whom close monitoring of intraocular pressure during treatment is advised.


Q: Does Pred Forte contain any preservatives?

A: Yes, the formulation of Pred Forte contains benzalkonium chloride. This is a common substance used as a preservative in many ophthalmic solutions.

How should Pred Forte 1% be stored and disposed of?

How to Store and Dispose of Pred Forte 1%

Pred Forte 1% (prednisolone acetate ophthalmic suspension) must be stored under specific conditions to maintain its effectiveness, as mandated by regulatory labeling.


Storage Requirements

Requirement Condition
Temperature Store at or below 25°C (77°F).
Handling Do not freeze and store the container in an upright position.
Container Rule Keep the container tightly closed when not in use.
Child Safety Keep out of the sight and reach of children.

Stability and Disposal

The suspension must be discarded 28 days or four weeks after the date of first opening the container. Any unused or expired medicine must be disposed of in a manner that complies with local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pred Forte 1% found in:

A-Z Index: